Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

• Published in: British Journal of Haematology Vol. 182; no. 4; pp. 583 - 586
• Main Authors: Dang, Nam H., Ogura, Michinori, Castaigne, Sylvie, Fayad, Luis E., Jerkeman, Mats, Radford, John, Pezzutto, Antonio, Bondarenko, Igor, Stewart, Douglas A., Shnaidman, Michael, Sullivan, Sharon, Vandendries, Erik, Tobinai, Kensei, Ramchandren, Radhakrishnan, Hamlin, Paul A., Giné, Eva, Ando, Kiyoshi
• Format: Journal Article
• Language: English
• Published: England Wiley 01.08.2018; Blackwell Publishing Ltd
• Subjects: Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibody-drug conjugate; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; B-cell non-Hodgkin lymphoma; Cancer and Oncology; Cancer och onkologi; CD22; Chemotherapy; Clinical Medicine; Female; Hematology; Humans; Immunotherapy; Inotuzumab ozogamicin; Klinisk medicin; Letter; Lymphocytes B; Lymphoma; Lymphoma, B-Cell - drug therapy; Lymphoma, B-Cell - mortality; Lymphoma, B-Cell - pathology; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Middle Aged; Monoclonal antibodies; Non-Hodgkin's lymphoma; ResearchInstitutes_Networks_Beacons/mcrc; name=Manchester Cancer Research Centre; Rituximab; Rituximab - administration & dosage; Rituximab - adverse effects; Targeted cancer therapy; B-cell non-Hodgkin lymphoma; antibody-drug conjugate; inotuzumab ozogamicin; CD22; rituximab